A fourteen-day repeated dose oral toxicity study of APFO in rats.
Ammonium perfluoroocanoate (APFO) was repeatedly administered orally to male Crj:CD(SD)IGS rats for 14 days. Doses of APFO were 0, 0.5, 5, and 50 mg/kg. Significant increases and increasing tendencies in absolute/relative weight of the liver and no change in weight of the spleen were observed in all groups. Although inductions of mitochondrion- and peroxisome-specific enzymes were increased, no decrease was seen in any hematological parameter of lipid metabolism. Red blood cell count, hemoglobin concentration, and hematocrit or these tendencies showed a significant decrease or a tendency to decrease, but no influence on lymphocyte subsets was noted. Secondary inhibition of immunocompetent cells, previously reported for mice, was not seen in this study of rats.
Iwai
Hiroyuki
H
Daikin Industries, Ltd., Osaka, Japan. hiroyuki.iwai@daikin.co.jp
Yamashita
Kotaro
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001772:Blood Cell Count; D001774:Blood Chemical Analysis; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002210:Caprylates / Q000633:toxicity*; D002784:Cholesterol / Q000097:blood; D005466:Fluorocarbons / Q000633:toxicity*; D007111:Immunity, Cellular / Q000187:drug effects*; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000187:drug effects; D008297:Male; D009929:Organ Size / Q000187:drug effects; D020675:Peroxisomes / Q000378:metabolism; D010743:Phospholipids / Q000097:blood; D051381:Rats; D014280:Triglycerides / Q000097:blood
D000911:Antibodies, Monoclonal; D001786:Blood Glucose; D002210:Caprylates; D005466:Fluorocarbons; D010743:Phospholipids; D014280:Triglycerides; C023036:perfluorooctanoic acid; D002784:Cholesterol